Impact of dose modification of immune-checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.

M. Veron (La Tronche, France), T. Pierret (Lyon, France), M. Perol (Lyon, France), J. Benet (La Tronche, France), N. Denis (La Tronche, France), D. Moro-Sibilot (La Tronche, France), A. Swalduz (Lyon, France), A. Toffart (La Tronche, France)

Source: International Congress 2022 – Identification of therapeutic strategies in lung cancer

Session: Identification of therapeutic strategies in lung cancer
Session type: Thematic Poster
Number: 1926

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Veron (La Tronche, France), T. Pierret (Lyon, France), M. Perol (Lyon, France), J. Benet (La Tronche, France), N. Denis (La Tronche, France), D. Moro-Sibilot (La Tronche, France), A. Swalduz (Lyon, France), A. Toffart (La Tronche, France). Impact of dose modification of immune-checkpoint inhibitors in lung cancer patients during the COVID-19 pandemic.. 1926

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.